The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer

Expert Rev Anticancer Ther. 2024 May 2:1-3. doi: 10.1080/14737140.2024.2349783. Online ahead of print.

Authors

Gianluca Ingrosso¹, Andrea Lancia², Eleonora Festa¹, Antonio Rosario Pisani³, Rita Bellavita¹, Cynthia Aristei¹, Beatrice Detti⁴

Affiliations

¹ Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy.
² Department of Radiation Oncology, Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy.
³ Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy.
⁴ Radiation Oncology Department, USL Centro Toscana - Prato, Prato, Italy.

PMID: 38682638
DOI: 10.1080/14737140.2024.2349783

No abstract available

Keywords: Cytoreductive radiotherapy; neoadjuvant radiotherapy; primary kidney cancer; renal cell carcinoma; stereotactic ablative radiotherapy.

Publication types

Editorial